Department of Internal Medicine, Faculty of Medicine, Dr. Soetomo Teaching Hospital, Airlangga University, Surabaya, 60115, Indonesia.
Department of Neurosurgery, Faculty of Medicine, Dr. Soetomo Teaching Hospital, Airlangga University, Surabaya, 60115, Indonesia.
F1000Res. 2022 Jun 21;11:684. doi: 10.12688/f1000research.111047.1. eCollection 2022.
: Diabetes mellitus has been perceived as the worsening factor for coronavirus disease 2019 (COVID-19), where diabetes mellitus patients with pre-existing inflammatory condition could develop acute respiratory disease syndrome as well as multi-organ dysfunction. Managing diabetes mellitus amidst severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is also a matter of concern as several antidiabetic therapies could affect the progression of COVID-19. This study aimed to provide the clinical characteristics and outcomes of patients with both COVID-19 and diabetes mellitus receiving blood glucose lowering therapies and COVID-19 symptomatic treatments. : This retrospective study was performed on 260 medical records of patients hospitalized between May 2020 to February 2021 in East Java, Indonesia. Patients were confirmed COVID-19 positive based on the results from real time polymerase chain reaction (RT-PCR) using nasal swab samples collected on hospital admission. Data included were demographic characteristics, COVID-19 symptoms, severity of COVID-19, comorbidities (other than diabetes mellitus), fasting blood glucose (FBG), and 2-hours post-prandial blood glucose (2hPBG), and outcomes. : Most of the patients had age range of 41-60 years old (76.1%) with more than a half of the subjects (60%) were obese. Patients with uncontrolled diabetes were distributed evenly among the COVID-19 severities (74.3% in asymptomatic group, 73.6% in mild group, and 74.1% in moderate group). There were reductions in FBG and 2hPBG levels measured before (210.75±81.38 and 271.19±100.7 mg/dL, respectively) and after the treatment (181.03±68.9 and 222.01±86.96 mg/dL, respectively). All patients received multivitamin and symptomatic treatment for COVID-19. Oral antidiabetic drug (57.6%) and insulin (28.8%) were administered to lower the blood glucose level of the patients. As many as 96.9% patients survived, while 3.1% died. : COVID-19 could affect the blood glucose level, suggesting the importance of antihyperglycemic therapies among patients with both COVID-19 and diabetes mellitus.
糖尿病被认为是 2019 年冠状病毒病（COVID-19）的恶化因素，患有预先存在炎症的糖尿病患者可能会发展为急性呼吸窘迫综合征和多器官功能障碍。在严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染期间管理糖尿病也是一个值得关注的问题，因为几种抗糖尿病疗法可能会影响 COVID-19 的进展。本研究旨在提供同时患有 COVID-19 和糖尿病并接受降血糖治疗和 COVID-19 症状治疗的患者的临床特征和结局。
本回顾性研究对 2020 年 5 月至 2021 年 2 月期间在印度尼西亚东爪哇住院的 260 例患者的病历进行了分析。患者的 COVID-19 阳性结果是基于入院时采集的鼻拭子样本的实时聚合酶链反应（RT-PCR）结果确定的。数据包括人口统计学特征、COVID-19 症状、COVID-19 严重程度、合并症（除糖尿病以外）、空腹血糖（FBG）和餐后 2 小时血糖（2hPBG）以及结局。
大多数患者的年龄在 41-60 岁之间（76.1%），其中超过一半的患者（60%）肥胖。患有未控制的糖尿病的患者在 COVID-19 的严重程度中分布均匀（无症状组为 74.3%，轻症组为 73.6%，中度组为 74.1%）。治疗前后 FBG 和 2hPBG 水平均降低（分别为 210.75±81.38 和 271.19±100.7 mg/dL）。所有患者均接受了维生素和 COVID-19 对症治疗。口服降糖药（57.6%）和胰岛素（28.8%）用于降低患者的血糖水平。96.9%的患者存活，3.1%的患者死亡。
COVID-19 可能会影响血糖水平，这表明同时患有 COVID-19 和糖尿病的患者需要进行抗高血糖治疗。
